CYP2D40 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the CYP2D40 enzyme, which is a member of the cytochrome P450 superfamily. The CYP2D40 enzyme is involved in the oxidative metabolism of a variety of substrates, including endogenous molecules such as hormones, neurotransmitters, and fatty acids, as well as exogenous compounds like drugs and environmental chemicals. CYP2D40 functions by catalyzing the monooxygenation of its substrates, a reaction that introduces an oxygen atom into the substrate molecule. This process is critical for enhancing the solubility of these substrates, facilitating their subsequent metabolism, conjugation, or excretion from the body. As part of the broader cytochrome P450 family, CYP2D40 plays a vital role in maintaining metabolic balance and detoxification, particularly in the liver where these enzymes are highly expressed.
Inhibitors of CYP2D40 are typically small molecules that bind to the enzyme's active site, thereby preventing it from catalyzing the oxidation of its substrates. These inhibitors may work by occupying the substrate-binding pocket, blocking the natural substrates from accessing the catalytic site, or by inducing conformational changes that diminish the enzyme's catalytic efficiency. The development of CYP2D40 inhibitors involves detailed structural analysis of the enzyme, focusing on the regions critical for substrate recognition and catalytic activity. By inhibiting CYP2D40, researchers can investigate its specific role in various metabolic pathways and understand how the inhibition of this enzyme affects the metabolism of its substrates within the broader network of cytochrome P450-mediated reactions. The study of CYP2D40 inhibitors is essential for gaining insights into the enzyme's substrate specificity, its interaction with other metabolic enzymes, and its overall contribution to the detoxification processes within the body. This research enhances our understanding of the functional diversity of the cytochrome P450 family and underscores the importance of these enzymes in regulating the metabolism and biotransformation of a wide range of chemical entities within biological systems.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Antifungal agent in research acting as a potential direct inhibitor of CYP2D40, interfering with anandamide epoxidase activity. Modifies mitochondrial functions, hindering the predicted participation in anandamide metabolism. | ||||||
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
Antifungal agent in research potentially impacting CYP2D40 by suppressing anandamide epoxidase activity. Influences mitochondrial dynamics, hindering the predicted involvement in anandamide metabolic processes. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
H2 receptor antagonist with potential as a direct inhibitor of CYP2D40, interfering with anandamide epoxidase activity. Alters mitochondrial functions, hindering the predicted participation in anandamide metabolism. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $78.00 $142.00 | 23 | |
Antifungal agent in research with potential direct inhibition of CYP2D40, interfering with anandamide epoxidase activity. Modifies mitochondrial dynamics, hindering the predicted involvement in anandamide metabolic processes. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $124.00 | 7 | |
Antiretroviral agent in research with potential direct inhibition of CYP2D40, interfering with anandamide epoxidase activity. Modifies mitochondrial functions, hindering the predicted participation in anandamide metabolism. | ||||||
Erythromycin | 114-07-8 | sc-204742 sc-204742A sc-204742B sc-204742C | 5 g 25 g 100 g 1 kg | $57.00 $245.00 $831.00 $1331.00 | 4 | |
Macrolide antibiotic potentially acting as a direct inhibitor of CYP2D40, interfering with anandamide epoxidase activity. Alters mitochondrial dynamics, hindering the predicted involvement in anandamide metabolic processes. | ||||||
Quinine | 130-95-0 | sc-212616 sc-212616A sc-212616B sc-212616C sc-212616D | 1 g 5 g 10 g 25 g 50 g | $79.00 $104.00 $166.00 $354.00 $572.00 | 1 | |
Antimalarial agent in research potentially inhibiting CYP2D40 directly by interfering with anandamide epoxidase activity. Modifies mitochondrial and intracellular dynamics, hindering the predicted participation in anandamide metabolism. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Calcium channel blocker with potential direct inhibition of CYP2D40, interfering with anandamide epoxidase activity. Modifies mitochondrial functions, hindering the predicted involvement in anandamide metabolic processes. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker with potential direct inhibition of CYP2D40, interfering with anandamide epoxidase activity. Alters mitochondrial dynamics, hindering the predicted participation in anandamide metabolic processes. | ||||||
Ranitidine | 66357-35-5 | sc-203679 | 1 g | $193.00 | ||
H2 receptor antagonist with potential direct inhibition of CYP2D40, interfering with anandamide epoxidase activity. Modifies mitochondrial functions, hindering the predicted involvement in anandamide metabolic processes. | ||||||